Metacel Pharmaceuticals

Metacel Pharmaceuticals was a U.S. specialty pharmaceutical company focused on oral liquid prescription medicines for patients with debilitating conditions. Its principal marketed product was Ozobax and later Ozobax DS, oral baclofen solutions indicated for spasticity associated with multiple sclerosis, with potential value in patients with spinal cord injury and related disorders. The company appears to have operated as a focused commercial-stage asset company rather than a broad clinical-development biotech, with a limited pipeline centered on baclofen oral solution formulations. In July 2024, Metacel was acquired as an affiliate of Sabal Therapeutics by Rosemont Pharmaceuticals, and its legacy website now redirects users to Rosemont Pharmaceuticals LLC. As a result, Metacel no longer appears to operate as an independent active company.